STERIS (NYSE:STE) Releases Earnings Results, Beats Expectations By $0.03 EPS

STERIS (NYSE:STE) released its earnings results on Wednesday. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.03, Briefing.com reports. STERIS had a return on equity of 13.91% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the company posted $2.03 earnings per share. The company’s revenue was up 7.3% compared to the same quarter last year. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Price Performance

Shares of NYSE:STE traded up $1.87 during midday trading on Friday, reaching $217.37. 498,076 shares of the company’s stock traded hands, compared to its average volume of 487,954. The company has a market cap of $21.44 billion, a P/E ratio of 49.20 and a beta of 0.85. The company has a fifty day simple moving average of $232.73 and a two-hundred day simple moving average of $227.52. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. STERIS has a 1 year low of $195.47 and a 1 year high of $248.24.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 1.05%. The ex-dividend date is Tuesday, November 19th. STERIS’s payout ratio is 52.05%.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.14% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have recently commented on STE shares. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research report on Friday. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. Finally, KeyCorp boosted their price target on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $253.00.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.